Cross section measurements of 151Eu(3He,5n) reaction: new opportunities for medical alpha emitter 149Tb production

Moiseeva, A. N.; Алиев, Р. А.; Унежев, В. Н.; Zagryadskiy, V. A.; Latushkin, S. T.; Aksenov, N. V.; Gustova, N. S.; Voronuk, M. G.; Starodub, G. Ya.; Ogloblin, A. A.

doi:10.1038/s41598-020-57436-6

Cited by 27 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The advantages are a wider availability of the target material ( 151 Eu is more abundant than 152 Gd) and a much easier radiochemical process with the possibility to remove 151 Eu after irradiation in aqueous solution as a 151 Eu(II) species. However, the main limitation is the ability to have access to an equipment with a high intensity 3 He-beam [ 273 , 274 , 275 ].…”

Section: Terbium-149mentioning

confidence: 99%

Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”

et al. 2021

View full text Add to dashboard Cite

Among all existing radionuclides, only a few are of interest for therapeutic applications and more specifically for targeted alpha therapy (TAT). From this selection, actinium-225, astatine-211, bismuth-212, bismuth-213, lead-212, radium-223, terbium-149 and thorium-227 are considered as the most suitable. Despite common general features, they all have their own physical characteristics that make them singular and so promising for TAT. These radionuclides were largely studied over the last two decades, leading to a better knowledge of their production process and chemical behavior, allowing for an increasing number of biological evaluations. The aim of this review is to summarize the main properties of these eight chosen radionuclides. An overview from their availability to the resulting clinical studies, by way of chemical design and preclinical studies is discussed.

show abstract

Section: Terbium-149mentioning

confidence: 99%

Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Of the lightion induced production methods, the bombardment of 151 Eu with 70 MeV 3 He can yield 150 MBq/μA of 149 Tb during an 8 h irradiation which is appropriate for therapeutic applications (Moiseeva et al 2020 ). The radiochemical purification of 149 Tb from the Eu target is relatively straightforward however the limited number of high-intensity 3 He beams worldwide significantly limits potential production via this method.…”

Section: Terbium: 149 Tb ...mentioning

confidence: 99%

Cutting edge rare earth radiometals: prospects for cancer theranostics

Sadler

Hogan

Fraser

et al. 2022

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

Background With recent advances in novel approaches to cancer therapy and imaging, the application of theranostic techniques in personalised medicine has emerged as a very promising avenue of research inquiry in recent years. Interest has been directed towards the theranostic potential of Rare Earth radiometals due to their closely related chemical properties which allow for their facile and interchangeable incorporation into identical bifunctional chelators or targeting biomolecules for use in a diverse range of cancer imaging and therapeutic applications without additional modification, i.e. a “one-size-fits-all” approach. This review will focus on recent progress and innovations in the area of Rare Earth radionuclides for theranostic applications by providing a detailed snapshot of their current state of production by means of nuclear reactions, subsequent promising theranostic capabilities in the clinic, as well as a discussion of factors that have impacted upon their progress through the theranostic drug development pipeline. Main body In light of this interest, a great deal of research has also been focussed towards certain under-utilised Rare Earth radionuclides with diverse and favourable decay characteristics which span the broad spectrum of most cancer imaging and therapeutic applications, with potential nuclides suitable for α-therapy (149Tb), β−-therapy (47Sc, 161Tb, 166Ho, 153Sm, 169Er, 149Pm, 143Pr, 170Tm), Auger electron (AE) therapy (161Tb, 135La, 165Er), positron emission tomography (43Sc, 44Sc, 149Tb, 152Tb, 132La, 133La), and single photon emission computed tomography (47Sc, 155Tb, 152Tb, 161Tb, 166Ho, 153Sm, 149Pm, 170Tm). For a number of the aforementioned radionuclides, their progression from ‘bench to bedside’ has been hamstrung by lack of availability due to production and purification methods requiring further optimisation. Conclusions In order to exploit the potential of these radionuclides, reliable and economical production and purification methods that provide the desired radionuclides in high yield and purity are required. With more reactors around the world being decommissioned in future, solutions to radionuclide production issues will likely be found in a greater focus on linear accelerator and cyclotron infrastructure and production methods, as well as mass separation methods. Recent progress towards the optimisation of these and other radionuclide production and purification methods has increased the feasibility of utilising Rare Earth radiometals in both preclinical and clinical settings, thereby placing them at the forefront of radiometals research for cancer theranostics.

show abstract

“…The decay scheme for 149 Tb is quite favorable since it releases short-range α particles from only one radionuclide, with complementary γ emissions and positrons that can be employed for imaging purposes in an "alpha-PET" combination [23,24]. Having only one α-emitter in its decay scheme implies a minimal toxicity from daughter recoil during radioactive decay, which should reduce excessive dose burden [25].…”

Section: Alpha Emitter Decay Propertiesmentioning

confidence: 99%

“…This method results in high yield production of 149 Tb (3 GBq for an 8 h irradiation), and is advantageous due to target material availability and relatively simple radiochemical processing. The main drawback is the limited availability of high intensity 3 He beams [25].…”

Section: Tbmentioning

confidence: 99%

“…149 Tb forms +3 and +4 oxidation states and can be chelated with DOTA conjugates [59], and it is particularly attractive since there are no α-emitting progeny presenting a redistribution issue upon release from the chelator. Radiolabeling using bifunctional chelators such as DOTA and DTPA has been well developed, giving a clear advantage over alpha emitters such as 211 At and 223 Ra [25]. One study using [ 149 Tb]Tb-DOTANOC achieved high-quality PET images of an AR42J tumor-bearing mouse, demonstrating the exceptional potential of 149 Tb to combine α-therapy with PET in "alpha-PET" using a single radionuclide [59].…”

Section: Tbmentioning

confidence: 99%

See 1 more Smart Citation

Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications

2020

View full text Add to dashboard Cite

This review outlines the accomplishments and potential developments of targeted alpha (α) particle therapy (TAT). It discusses the therapeutic advantages of the short and highly ionizing path of α-particle emissions; the ability of TAT to complement and provide superior efficacy over existing forms of radiotherapy; the physical decay properties and radiochemistry of common α-emitters, including 225Ac, 213Bi, 224Ra, 212Pb, 227Th, 223Ra, 211At, and 149Tb; the production techniques and proper handling of α-emitters in a radiopharmacy; recent preclinical developments; ongoing and completed clinical trials; and an outlook on the future of TAT.

show abstract

Cross section measurements of 151Eu(3He,5n) reaction: new opportunities for medical alpha emitter 149Tb production

Cited by 27 publications

References 27 publications

Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”

Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”

Cutting edge rare earth radiometals: prospects for cancer theranostics

Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications

Contact Info

Product

Resources

About